BP
ECYT

Ballentine Partners’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Ballentine Partners’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-35,732
Closed -$185K – 166
2015
Q2 		$185K Hold
35,732
– – 0.02% 158
2015
Q1 		$224K Hold
35,732
– – 0.02% 145
2014
Q4 		$225K Hold
35,732
– – 0.03% 142
2014
Q3 		$217K Hold
35,732
– – 0.03% 134
2014
Q2 		$235K Hold
35,732
– – 0.03% 126
2014
Q1 		$851K Hold
35,732
– – 0.1% 53
2013
Q4 		$382K Hold
35,732
– – 0.04% 103
2013
Q3 		$476K Hold
35,732
– – 0.06% 77
2013
Q2 		$469K Buy
+35,732
New +$482K 0.06% 67

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ballentine Partners's ECYT Position: Q3 2015 in Review

Ballentine Partners sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2015, closing a stake of 35,732 shares — an estimated $185K sold.

Ballentine Partners first reported a position in ECYT in Q2 2013 and held it in 9 quarters. The position peaked at $851K in Q1 2014. 104 funds tracked by Wall St. Rank hold ECYT as of Q3 2015.

  • Ballentine Partners reported no remaining Endocyte, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Ballentine Partners sold 35,732 Endocyte, Inc. Common Stock shares in Q3 2015, an estimated $185K.
  • Ballentine Partners first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 9 quarters.
  • Ballentine Partners's Endocyte, Inc. Common Stock position peaked at $851K in Q1 2014.
  • 104 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2015.

Based on Ballentine Partners's 13F filing for Q3 2015, filed 3 Nov 2015.